Arch Biopartners Inc. ARCH.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · archbiopartners.com
Arch Biopartners Inc. is a Toronto-based clinical-stage biopharmaceutical company developing novel therapeutics for acute and chronic kidney disease. Its lead candidate LSALT Peptide is in Phase 2 clinical trials for inflammation-related acute kidney injury in cardiac surgery patients, and it also develops cilastatin for toxin-related acute kidney injury via dipeptidase-1 inhibition.
Key ratios
FreeCashFlowOnSale TTM -9.68
FreeCashFlowOnSale 2025 -5.74
FreeCashFlowOnSale 2024 -1.1
FreeCashFlowOnSale 2023 -0.12
NetIncomeMargin TTM -1.83
NetIncomeMargin 2024 -1.85
NetIncomeMargin 2023 -1.68
ReturnOnAssets TTM -5.24
ReturnOnAssets 2025 -1.36
ReturnOnAssets 2024 -2.05
ReturnOnAssets 2023 -2.02
Recent news
Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans
2026-06-04 · GlobeNewswire
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
2026-05-22 · GlobeNewswire
Arch Biopartners Closes Non-Brokered Private Placement
2026-04-02 · GlobeNewswire
Arch Biopartners Arranges Non-Brokered Private Placement
2026-03-30 · GlobeNewswire